Betting Against
Read this first: nobody can show you who is short
A 13F does not disclose short positions. Short sales are exempt from it, so no site can list a fund's shorts, including this one. Two different things are knowable and this page keeps them apart: short interest tells you how heavily a stock is shorted by the whole market and names nobody, and 13F puts tell you which named fund holds put options.
Neither one sees a swap. A fund short through total-return swaps or plain borrow appears in neither dataset, which is why Archegos was invisible until it was not. An empty put list is not evidence that nobody is betting against a name.
Most shorted
By short interest as a percent of float. Above 100% is real rather than an error: borrowed shares get sold and re-lent. Settlement July 31, 2026, so this is positioning as of that date and not today.
| Symbol | % of float short | Shares short | Days to cover | vs last | Price | Today |
|---|---|---|---|---|---|---|
| QS QuantumScape Corporation Class A Common Stock | 113.3% | 102.3M | 3.2 | -2% | $6.16 | -3.4% |
| EOSE Eos Energy Enterprises, Inc. Class A Common Stock | 61.9% | 115.7M | 4.4 | +9% | $4.16 | -1.9% |
| TE T1 Energy Inc. | 43.4% | 60.5M | 1.4 | +24% | $4.79 | -2.2% |
| ONDS Ondas Inc. Common Stock | 41.8% | 235.0M | 1.9 | +2% | $8.91 | -8.8% |
| LENZ LENZ Therapeutics, Inc. Common Stock | 40.8% | 11.3M | 11.8 | -5% | $4.60 | -8.7% |
| JACK Jack in the Box Inc. | 38.5% | 6.8M | 9.4 | -2% | $18.76 | -0.1% |
| QXO QXO, Inc. | 37.0% | 93.6M | 4.6 | -11% | $14.89 | -0.9% |
| NNE Nano Nuclear Energy Inc. Common Stock | 35.0% | 15.3M | 7.1 | +10% | $20.52 | +7.9% |
| SERV Serve Robotics Inc. Common Stock | 32.0% | 26.5M | 8.6 | +9% | $4.94 | +2.3% |
| NAVI Navient Corporation | 31.7% | 10.3M | 13.8 | +0% | $9.24 | +4.5% |
| ARCT Arcturus Therapeutics Holdings Inc. Common Stock | 31.6% | 7.2M | 16.5 | +3% | $7.86 | +3.4% |
| BBAI BigBear.ai Holdings, Inc. | 30.9% | 147.5M | 5.7 | +1% | $3.34 | +2.5% |
| PLAY Dave & Buster's Entertainment, Inc. | 30.5% | 9.8M | 7.9 | -14% | $10.63 | +2.5% |
| NVAX Novavax Inc | 30.4% | 45.7M | 16.6 | +4% | $8.14 | +2.3% |
| CAPR Capricor Therapeutics Inc | 29.8% | 16.0M | 2.1 | +3% | $4.21 | +0.5% |
| CLSK CLEANSPARK INC | 29.4% | 74.0M | 3.3 | -5% | $11.52 | -5.4% |
| TNGX Tango Therapeutics, Inc. | 29.2% | 44.6M | 19.1 | +4% | $25.65 | +0.3% |
| HRTX Heron Therapeutics, Inc. | 29.2% | 43.2M | 24.4 | +1% | $0.334 | -1.9% |
| CMPX Compass Therapeutics, Inc. Common Stock | 29.0% | 39.9M | 17.6 | +1% | $2.26 | -4.6% |
| IMRX Immuneering Corporation Class A Common Stock | 28.3% | 15.4M | 20.4 | +1% | $5.20 | +2.6% |
| STOK Stoke Therapeutics, Inc. Common Stock | 28.1% | 15.8M | 27.7 | +1% | $31.31 | -5.0% |
| RUN Sunrun Inc | 27.8% | 64.7M | 7.2 | -2% | $9.86 | +0.2% |
| SLS SELLAS Life Sciences Group, Inc. Common Stock | 27.6% | 55.0M | 7.9 | -1% | $12.36 | +5.0% |
| BYND Beyond Meat, Inc. Common Stock | 26.8% | 130.5M | 5.5 | -0% | $0.407 | -1.7% |
| SNDX Syndax Pharmaceuticals, Inc. | 26.7% | 22.7M | 18.6 | +9% | $19.08 | -3.6% |
Being added to
Short interest rising fastest since the prior settlement, among names with a real base already on. This is fresh money taking the other side, not an old position sitting there.
Funds holding puts
Named 13F filers with put positions. Quarterly and roughly 45 days behind, so treat it as what a fund held at quarter end rather than what it holds now.
How to read these numbers
- % of float short is the crowding. It says how much of the tradeable supply is already sold short, which is what makes covering move a price.
- Days to cover is how many normal sessions the short base would need to buy back. A high number means the exit is narrow.
- Exposure on a put is notional, not money at risk. A $912M put is 5,000,000 shares of exposure; the premium paid is a fraction of that and is never disclosed.
- A crowded short is not a signal on its own. It says the disagreement is large, not who is right. Names stay heavily shorted for years.
- Float we cannot corroborate is left blank rather than shown. A stale share count inflates the percentage badly, and a wrong 205% is worse than an honest gap.
Research and commentary, not investment advice.